AstraZeneca ((AZN)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
AstraZeneca is conducting a Phase III study titled ‘A Randomised, Open-Label, Phase III Study of Saruparib (AZD5305) Plus Camizestrant Compared With Physician’s Choice CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant for the First-Line Treatment of Patients With BRCA1, BRCA2, or PALB2 Mutations and Hormone Receptor Positive, HER2-Negative Advanced Breast Cancer.’ The study aims to evaluate the efficacy of saruparib (AZD5305) combined with camizestrant against standard treatments in patients with specific genetic mutations in advanced breast cancer.
The interventions being tested include saruparib, a PARP1 inhibitor, and camizestrant, a next-generation SERD. These are compared against physician’s choice of CDK4/6 inhibitors and endocrine therapies, which are standard treatments for this type of cancer.
The study employs a randomized, open-label, parallel assignment model with a primary purpose of treatment. Participants are randomly assigned to one of three groups to receive different combinations of the test drugs or standard treatments.
The study began on August 1, 2024, with an estimated completion date yet to be announced. The last update was submitted on July 22, 2025, indicating ongoing recruitment and progress.
This study update could influence AstraZeneca’s stock performance positively by showcasing its commitment to innovative cancer treatments. Investor sentiment may be bolstered by the potential for new, effective therapies in a competitive oncology market.
The study is ongoing, with further details available on the ClinicalTrials portal.